** Shares of drug developer Leap Therapeutics LPTX.O fall 67.1% to 74 cents premarket
** Co says it will not move forward with late-stage trials of its drug, sirexatamab, in patients with gastric cancer
** Says drug will show negative results for ongoing mid-stage trial's main goal of progression free survival when study completes
** Will explore partnership opportunities to test sirexatamab in combination with a type of cancer drugs called anti-PD-1 antibodies for treatment of gastric cancer and other diseases
** Up to last close, stock down 7.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。